Researchers at MUSC Hollings Cancer Center and international collaborators have developed a new blood test that could help patients at high risk for lymphoma get to a biopsy and treatment sooner. The Access to Diagnosis using Liquid Biopsy (ADLiB) platform combines multiple genetic clues found in the blood with machine learning to estimate a patient’s likelihood of having lymphoma. In an initial study of 124 patients in South Africa, the platform correctly identified patients with lymphoma 95% of the time. Rather than replacing a tissue biopsy, researchers envision ADLiB as a tool to fast-track patients who need further testing, particularly in rural and resource-limited settings where access to specialized pathology expertise may be limited.

What does it take to bring lab-grade diagnostics into the home? New research from the University of Illinois has a practical answer: the VPodDuo, a fluorescence-testing device the size of an AirPods case, capable of detecting everything from HIV to cancer biomarkers.

The aberrant activation of the mTOR pathway and its crosstalk with other signaling cascades represent key drivers of hepatocellular carcinoma (HCC) progression. mTOR-mediated ferroptosis suppression has been implicated in HCC resistance to chemotherapy. This study aimed to elucidate the mechanisms underlying mTOR inhibitor resistance and to evaluate the therapeutic potential of multidrug combinations in β-catenin-mutant HCC.

Researchers have identified a previously underappreciated relationship between SUCLA2 and USP10 that strongly correlates with distant metastasis-free survival (DMFS) in breast cancer patients. More importantly, the study shows that this prognostic relationship changes dramatically depending on whether patients receive treatment, highlighting the importance of considering molecular interactions when predicting clinical outcomes.

Growth impairment is a common late effect of childhood stem cell transplantation. A Japan-wide study found that growth hormone therapy improves adult height, but prior radiation therapy and transplant-related complications negatively affect how much children benefit.

A newly identified role for C/EBPγ reveals how lung adenocarcinoma cells simultaneously acquire invasive properties and strengthen DNA repair. The findings uncover a potential driver of treatment resistance and a promising therapeutic target.